Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Provided By GlobeNewswire
Last update: Mar 20, 2025
CTIM-76 first patient dosed in January 2025
Cash and cash equivalents of $94.4 million as of December 31, 2024
Company expects its cash and cash equivalents will continue to fund operations into 2027
Read more at globenewswire.com
